Cytodyn Inc (CYDY)

[JPG77]

You said Ken was CEO and deserved credit for rescuing PRO-140 from the shelf, yet it was Nader who was CEO when it was acquired. Now Ken may have signed the initial papers with the intent to acquire it, but clearly wasn't in the drivers seat throughout the actual acquisition. Additionally, as you mentioned below, Ken's area of expertise was real estate, which explains why he stepped down to let to Nader take the lead, especially given that Nader was the Managing Director of "Business Development" and obviously who would have been responsible for new business initiatives. As you should know, CEO's hire good business development talent who are are responsible for identifying new opportunities, and the CEOs normally follow their lead.

Sept 11, 2012 - CytoDyn Inc. Names Dr. Nader Pourhassan New CEO
https://investorshub.advfn.com/secure/post_reply.aspx?message_id=165779555

"Prior to his new position as CEO, Dr. Pourhassan served as the Company’s Managing Director of Business Development, and before that, as its Chief Operating Officer."

Oct 18, 2012 - CytoDyn Announces Acquisition of Pro 140
https://www.fiercepharma.com/pharma/cytodyn-announces-acquisition-of-pro-140

“CytoDyn is a company focused on the development of monoclonal antibodies for the treatment of immune deficiency viruses. Pro 140 is the most advanced cell-specific monoclonal antibody to date being tested for the treatment of HIV. This makes it a perfect fit for our company. We believe that Pro 140 represents an entirely new approach to treating HIV. We are excited about taking it forward through the next stages of clinical development,” said Dr. Nader Pourhassan, CytoDyn’s interim President and CEO.

I can’t answer why Ken stepped down. I know he had other projects he was working on that were closer to his area of expertise ( real estate). Perhaps he felt the company was on the right track with his acquisition of Pro 140 and felt it was time to move on.